Wednesday, July 8, 2026

Patent intelligence · US

US 10023879

Minimal volume reprogramming of mononuclear cells

granted A61KA61K2035/124A61K35/51A61K35/545
Status granted
Linked drugs 2
Pipeline programs 6
Years to expiry 12
Applicant portfolio 53
Patent details — US 10023879
Jurisdiction
US
Status
granted
Grant date
Jul 17, 2018
Expiration
Jul 12, 2038
Claims
23
CPC classes
A61K, A61K2035/124, A61K35/51, A61K35/545
View on Google Patents ↗

Quick answer

US 10023879 (Minimal volume reprogramming of mononuclear cells) is held by Fate Therapeutics, Inc.. Status: granted. Granted Jul 17, 2018. Expires Jul 12, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
23
CPC classes
A61K, A61K2035/124, A61K35/51, A61K35/545

More from Fate Therapeutics, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12419870

    Compositions and methods for immune cell modulation in adoptive immunotherapies

    Fate Therapeutics, Inc. · Expires Sep 18, 2045

    granted
  2. US 12410403

    Methods and compositions for inducing hematopoietic cell differentiation

    Fate Therapeutics, Inc. · Expires Sep 4, 2045

    granted
  3. US 12398373

    Enhanced immune effector cells and use thereof

    Fate Therapeutics, Inc. · Expires Aug 21, 2045

    granted
  4. US 12385012

    Methods and compositions for inducing hematopoietic cell differentiation

    Fate Therapeutics, Inc. · Expires Aug 7, 2045

    granted
  5. US 12281329

    Compositions and methods for immune cell modulation in adoptive immunotherapies

    Fate Therapeutics, Inc. · Expires Apr 17, 2045

    granted
  6. US 12275955

    Combining iPSC derived effector cell types for immunotherapy use

    Fate Therapeutics, Inc. · Expires Apr 10, 2045

    granted
  7. US 12264322

    Minimal volume reprogramming of mononuclear cells

    Fate Therapeutics, Inc. · Expires Mar 27, 2045

    granted
  8. US 12247226

    Cellular reprogramming using temporal and transient plasmid vector expression system

    Fate Therapeutics, Inc. · Expires Mar 6, 2045

    granted

Frequently asked questions

What is US patent 10023879?

US 10023879 (Minimal volume reprogramming of mononuclear cells) is held by Fate Therapeutics, Inc.. Status: granted. Granted Jul 17, 2018. Expires Jul 12, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10023879?

Fate Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 53 pharmaceutical patents for this assignee.

When does US 10023879 expire?

Our index shows an expiration date of Jul 12, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.